Overview

Loss of Response of Adalimumab Biosimilar vs Adalimumab Original, in Inflammatory Bowel Disease.

Status:
Terminated
Trial end date:
2020-06-08
Target enrollment:
Participant gender:
Summary
Loss of response of the Adalimumab biosimilar compared with the original drug.
Phase:
Phase 4
Details
Lead Sponsor:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Treatments:
Adalimumab
Pharmaceutical Solutions